...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technological forecasting and social change >From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry
【24h】

From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry

机译：从小分子仿制药到生物仿制药：印度制药行业的技术升级和独特学习过程的模式

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology upgrading and creating new patterns of capability development. This raises the questions about factors and processes involved in technology upgrading in firms from developing countries. In this context, this paper explores the movement of Indian pharmaceutical firms from 'small molecule generics' towards targeting a new set of opportunities presented by the emergent biosimilar segment in the global generics market. Some leading Indian firms have adopted this technological upgrading route by making a gradual transition towards the development of biosimilar capabilities and using four case studies, this paper reveals internationalisations in form of overseas acquisitions and collaborations with MNCs formed the key basis of technology upgrading strategy for the Indian firms. This paper further shows the hiring of biotech scientists working in advanced countries increasing R&D investment and reorganisation of R&D contributed to managerial upgrading and played a significant role in creating firms' ability to absorb external knowledge.
机译：技术升级是发展中国家工业化和追赶的关键要素。可以理解的是，成功的技术升级与全球知识流与本地技术工作的耦合联系在一起。但是，技术和行业的不断变化的特性正在挑战技术升级和创建能力开发新模式的现有过程。这就提出了有关发展中国家公司技术升级所涉及的因素和过程的问题。在这种背景下，本文探讨了印度制药公司从“小分子仿制药”向全球仿制药新兴生物仿制药领域提出的一系列新机遇的转移。一些领先的印度公司采用了这种技术升级途径，逐步向生物仿制药能力的发展过渡，并使用四个案例研究。本文揭示了以海外收购形式进行的国际化以及与跨国公司的合作构成了技术升级战略的关键基础。印度公司。本文进一步显示，在发达国家聘用的生物技术科学家增加了R＆D投入，R＆D的重组有助于管理升级，并在建立公司吸收外部知识的能力方面发挥了重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号